Background Although several COVID-19 vaccines have been developed so far, they will not
be sufficient to meet the global demand. Development of a wider range of vaccines, with …

Background Multiple vaccine candidates against COVID-19 are currently being evaluated.
We evaluate the safety and immunogenicity protein of a novel SARS-CoV-2 virus receptor …

Background The ZF2001 vaccine, which contains a dimeric form of the receptor-binding
domain of severe acute respiratory syndrome coronavirus 2 and aluminum hydroxide as an …

Safe, efficacious, and deployable vaccines are urgently needed to control COVID-19 in the
large-scale vaccination campaigns. We report here the preclinical studies of an approved …

Background A range of safe and effective vaccines against SARS CoV 2 are needed to
address the COVID 19 pandemic. We aimed to assess the safety and efficacy of the COVID …

Background We assessed the efficacy of a receptor-binding domain (RBD)-based protein
subunit COVID-19 vaccine. Methods A randomised Phase-1/2 trial followed by a Phase-2 …

Safe and effective vaccines are still urgently needed to cope with the ongoing COVID-19
pandemic. Recently, we developed a recombinant COVID-19 vaccine (V-01) containing …

Background The ongoing COVID-19 pandemic warrants accelerated efforts to test vaccine
candidates. We aimed to assess the safety and immunogenicity of an inactivated severe …

Summary Background Although SARS-CoV-2 infection often causes milder symptoms in
children and adolescents, young people might still play a key part in SARS-CoV-2 …

Background The pandemic of COVID-19 raised the urgent need for safe and efficacious
vaccines against SARS-CoV-2. We evaluated the efficacy and safety of a new SARS-CoV-2 …